Omacetaxine
Sponsors
ChemGenex Pharmaceuticals, M.D. Anderson Cancer Center, Emory University, University of Florida, University of Colorado, Denver
Conditions
Acute Myelogenous Leukemia (AML)Hematologic TumorsHigh Grade Myelodysplastic SyndromesLeukemiaMyelodysplastic SyndromesRelapsed or Refractory Hematologic Malignancies
Phase 1
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
CompletedNCT00675350
Start: 2008-04-30End: 2009-01-31Updated: 2014-05-12
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
TerminatedNCT02141477
Start: 2015-05-06End: 2017-06-22Updated: 2018-02-13
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
WithdrawnNCT02835794
Start: 2016-08-31End: 2018-12-31Updated: 2017-05-03
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
Active, not recruitingNCT03564873
Start: 2018-09-17End: 2027-06-30Updated: 2025-12-11
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)
CompletedNCT04926285
Start: 2022-06-21End: 2025-02-06Updated: 2026-03-16
Phase 2
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
CompletedNCT01272245
Start: 2011-07-31End: 2017-01-31Updated: 2018-05-30
Omacetaxine for Consolidation and Maintenance
TerminatedNCT01873495
Start: 2013-05-31End: 2018-07-31Updated: 2019-09-24
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
CompletedNCT02159872
Start: 2015-05-18End: 2020-04-14Updated: 2021-06-09